Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1966]

ASCO 2023: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ASCO 2023: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

Axi-cel improves survival in early r/r large B-cell lymphoma

Dr Jason Westin - The University of Texas MD Anderson Cancer Center, Houston...

Axi-cel improves survival in early r/r large B-cell lymphoma ( Dr Jason Westin - The University of Texas MD Anderson Cancer Center, Houston, USA )

CDK4/6 inhibitors added to first line show no greater benefit when compared to...

Dr Gabe Sonke - Netherlands Cancer Institute, Amsterdam, Netherlands

CDK4/6 inhibitors added to first line show no greater benefit when compared to their use in second line therapy in HR+, HER2- ABC ( Dr Gabe Sonke - Netherlands Cancer Institute, Amsterdam, Netherlands )

FolRα-targeting antibody drug conjugate shows promise in recurrent epithelial...

Dr Ana Oaknin - Vall d´Hebron Institute of Oncology, Barcelona, Spain

FolRα-targeting antibody drug conjugate shows promise in recurrent epithelial ovarian cancer ( Dr Ana Oaknin - Vall d´Hebron Institute of Oncology, Barcelona, Spain )

Teclistamab for RRMM: Long term follow up data from MajesTEC-1

Prof Niels Van de Donk - Amsterdam University Medical Center, Amsterdam...

Teclistamab for RRMM: Long term follow up data from MajesTEC-1 ( Prof Niels Van de Donk - Amsterdam University Medical Center, Amsterdam, Netherlands )

Vaccine-immunotherapy combo for high risk melanoma: New data on distant...

Prof Muhammad Adnan Khattak - Fiona Stanley Hospital, Perth, Australia

Vaccine-immunotherapy combo for high risk melanoma: New data on distant metastasis-free survival ( Prof Muhammad Adnan Khattak - Fiona Stanley Hospital, Perth, Australia )

Trastuzumab deruxtecan gives strong anti-tumour activity and durable responses...

Dr Funda Meric-Bernstram - MD Anderson Cancer Center, Houston, USA

Trastuzumab deruxtecan gives strong anti-tumour activity and durable responses in multiple tumour types ( Dr Funda Meric-Bernstram - MD Anderson Cancer Center, Houston, USA )

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit and increases toxicity ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

ASCO 2023: Latest in mRCC

Dr Javier Puente, Dr Cristina Suárez, Prof Stéphane Oudard, Prof Viktor Grünwald

ASCO 2023: Latest in mRCC ( Dr Javier Puente, Dr Cristina Suárez, Prof Stéphane Oudard, Prof Viktor Grünwald )

Pembrolizumab improves OS in firstline treatment for unresectable advanced...

Dr Penelope Bradbury - Princess Margaret Cancer Centre, Toronto, Canada

Pembrolizumab improves OS in firstline treatment for unresectable advanced pleural mesothelioma ( Dr Penelope Bradbury - Princess Margaret Cancer Centre, Toronto, Canada )

Pembro plus chemo followed by resection and adjuvant pembro improves on...

Prof Heather Wakelee - Stanford Cancer Institute, Stanford, USA

Pembro plus chemo followed by resection and adjuvant pembro improves on standard of care for early NSCLC ( Prof Heather Wakelee - Stanford Cancer Institute, Stanford, USA )

PHE885 CAR-T cell therapy shows high response rates for r/r multiple myeloma in...

Prof Adam Sperling - Dana-Farber Cancer Institute, Boston, USA

PHE885 CAR-T cell therapy shows high response rates for r/r multiple myeloma in phase 1 ( Prof Adam Sperling - Dana-Farber Cancer Institute, Boston, USA )

More from ecancer